Literature DB >> 22341666

Safety of intravenous thrombolysis in acute ischemic stroke patients with saccular intracranial aneurysms.

Manoj K Mittal1, Raymond C S Seet, Yi Zhang, Robert D Brown, Alejandro A Rabinstein.   

Abstract

BACKGROUND: It is not known if the presence of unruptured intracranial aneurysms can increase the risk of hemorrhage after thrombolysis for acute ischemic stroke. The goal of our study was to evaluate the risk of hemorrhage after intravenous tissue plasminogen activator in acute stroke patients with intracranial aneurysms.
METHODS: This is a retrospective analysis of consecutive cases of patients with acute ischemic stroke who were treated with intravenous tissue plasminogen activator at Mayo Clinic between March 2002 and June 2011 and who were evaluated with invasive or noninvasive intracranial angiography. Univariate analyses were performed with the t, Chi-square, and Fisher exact tests where appropriate.
RESULTS: Intracranial angiograms were performed in 105 patients (85 magnetic resonance angiography, 19 computed tomography angiography, and 1 catheter arteriography). The mean age of the patients was 69 ± 14 years. The mean National Institutes of Health Stroke Scale score at admission was 8 ± 5. A total of 12 incidental saccular aneurysms were found in 10 (9.5%) patients, and all 10 of these patients were white. There were no subarachnoid hemorrhages during the hospital stay in any patient with or without intracranial aneurysm. The rates of symptomatic intracranial hemorrhage and 3-month clinical outcomes were similar in patients with or without intracranial aneurysms.
CONCLUSIONS: Intravenous thrombolysis was safe among our patients with acute ischemic stroke and incidental intracranial saccular aneurysm.
Copyright © 2013 National Stroke Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22341666     DOI: 10.1016/j.jstrokecerebrovasdis.2012.01.009

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  7 in total

1.  Fibrinolytic Enzyme Cotherapy Improves Tumor Perfusion and Therapeutic Efficacy of Anticancer Nanomedicine.

Authors:  Ameya R Kirtane; Tanmoy Sadhukha; Hyunjoon Kim; Vidhi Khanna; Brenda Koniar; Jayanth Panyam
Journal:  Cancer Res       Date:  2017-01-20       Impact factor: 12.701

2.  Association Between Unruptured Intracranial Aneurysms and Downstream Stroke.

Authors:  Monica Lin Chen; Ajay Gupta; Abhinaba Chatterjee; Darya Khazanova; Eda Dou; Hersh Patel; Gino Gialdini; Alexander E Merkler; Babak B Navi; Hooman Kamel
Journal:  Stroke       Date:  2018-09       Impact factor: 7.914

Review 3.  Absolute and Relative Contraindications to IV rt-PA for Acute Ischemic Stroke.

Authors:  Jennifer E Fugate; Alejandro A Rabinstein
Journal:  Neurohospitalist       Date:  2015-07

4.  Systemic thrombolysis in acute ischemic stroke patients with unruptured intracranial aneurysms.

Authors:  Nitin Goyal; Georgios Tsivgoulis; Ramin Zand; Vijay K Sharma; Kristian Barlinn; Shailesh Male; Aristeidis H Katsanos; Ulf Bodechtel; Sulaiman Iftikhar; Adam Arthur; Lucas Elijovich; Anne W Alexandrov; Andrei V Alexandrov
Journal:  Neurology       Date:  2015-09-25       Impact factor: 9.910

5.  Thrombolysis of an acute stroke presentation with an incidental unruptured aneurysm.

Authors:  J Ganesalingam; R Redwood; Ih Jenkins
Journal:  JRSM Cardiovasc Dis       Date:  2013-03-26

6.  Successful Thrombolysis despite Having an Incidental Unruptured Cerebral Aneurysm.

Authors:  Diana Briosa E Gala; André Almeida; Nadine Monteiro; Ana Paiva Nunes; Patrícia Ferreira; Nuno Mendonça; Alexandre Amaral-Silva; João Alcântara
Journal:  Case Rep Neurol Med       Date:  2014-11-24

7.  Prevalence, predictors and prognosis of incidental intracranial aneurysms in patients with suspected TIA and minor stroke: a population-based study and systematic review.

Authors:  Robert Hurford; Isabel Taveira; Wilhelm Kuker; Peter M Rothwell
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-11-04       Impact factor: 10.154

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.